ArticleBritish journal of cancer2026
HDAC5 stabilization by tubeimoside I suppresses cervical cancer metastasis via inhibiting H3K27ac/KPNA2 axis.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on active components from natural medicines inhibiting tumor via epigenetic regulation.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundCervical cancer poses a significant threat to women's health, and its metastasis is one of the leading causes of cancer-related deaths. Tubeimoside I (TBMS1) is a traditional Chinese medicinal herb with anticancer properties. We previously demonstrated the anticancer effect of TBMS1 in cervical cancer by inducing autophagy-related cell death. Nevertheless, whether and how TBMS1 prevents cervical cancer metastasis remain unclear.
methodsWound healing, transwell assays, and a lung metastasis mouse model were used to evaluate cell metastasis. Immunoprecipitation combined with site-directed mutagenesis was used to explore ubiquitination modifications and ubiquitinated sites of histone deacetylase 5 (HDAC5). HDAC5 depletion and RNA-seq analysis were conducted to investigate the anti-metastatic mechanism of TBMS1.
resultsWe show that low dose of TBMS1 inhibits cervical cancer metastasis. Mechanistically, TBMS1 binds to HDAC5 and prevents HDAC5 ubiquitination at lysine 137 and 538, leading to a decrease in proteasomal degradation of HDAC5. TBMS1-mediated HDAC5 upregulation further reduces the acetylation level of histone H3 lysine 27 (H3K27ac) and suppresses KPNA2 expression. HDAC5 depletion significantly attenuates TBMS1's anti-metastatic effect in cervical cancer.
conclusionOur study reveals HDAC5/H3K27ac/KPNA2 axis as the anti-metastatic mechanism of TBMS1 in cervical cancer, suggesting TBMS1 serves as a promising drug for cervical cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.